(Q85410833)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143687%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

title

Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143687%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Mats Remberger

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143687%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Olle Ringdén

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143687%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

11 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143687%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Hematology

17 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143687%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143687%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143687%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

822-824

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23143687%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12185-012-1218-3

17 February 2020

exact match

0 references

cites work

Variables predicting deep fungal infections in bone marrow transplant recipients.

1 reference

12 December 2020

Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT.

1 reference

12 December 2020

Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells

1 reference

12 December 2020

Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex

1 reference

12 December 2020

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

1 reference

12 December 2020

Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease

1 reference

12 December 2020

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

1 reference

12 December 2020

Immunomodulation by mesenchymal stem cells and clinical experience

1 reference

12 December 2020

Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy

1 reference

12 December 2020